What does the death of RiquentTM hold for the future of SLE?

    loading  Checking for direct PDF access through Ovid

Abstract

In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for RiquentTM (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years.

Related Topics

    loading  Loading Related Articles